Clinical Trial of RedHill’s Potential Crohn’s Disease Therapy Set to Continue as Planned

Clinical Trial of RedHill’s Potential Crohn’s Disease Therapy Set to Continue as Planned
RedHill Biopharma announced that an independent Data and Safety Monitoring Board (DSMB) recommended the company's MAP US clinical trial to continue as planned without any modifications. MAP US is an ongoing Phase 3 clinical trial (NCT01951326) testing RHB-104, a combination of antibiotics: rifabutin and clarithromycin with clofazamine, for the treatment of Crohn’s disease. It is a randomized, double-blind placebo-controlled study, meaning the participants are randomly allocated to either the drug or a placebo, and that neither they n
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *